Last updated: February 16, 2026
Product Overview
NDC 67253-0651 refers to a specific pharmaceutical product registered under the National Drug Code system. Exact details about the drug’s chemical composition, indications, and formulation are necessary for precise market analysis; however, based on typical industry classifications, this NDC is associated with biosimilar or branded biologic drugs.
Market Context
-
Therapeutic Area and Track Record
The NDC falls within biologics or biosimilars, which account for a growing share in specialty pharma. These drugs target complex chronic conditions, such as cancer, autoimmune diseases, or other rare conditions. Market share growth for biologics and biosimilars has led to increased competition and pricing pressures globally.
-
Regulatory Environment
The US Food and Drug Administration (FDA) follows specific pathways such as biosimilar approval procedures, affecting market entry timelines. Price regulation varies by region; in the US, no direct caps exist, but insurance company negotiations and rebates influence effective prices.
-
Market Size and Penetration
The biologics market in the US was valued at roughly $300 billion in 2022, with biosimilars estimated to encompass approximately 20-25% of that. Forecasts project biosimilars will reach 35-40% of the biologics market by 2027, driven by patent expirations and payer preference shifts.
-
Key Competitors and Alternatives
Major players include Amgen, Pfizer, Celltrion, and Samsung Bioepis. Established biologics often retain market dominance, but biosimilars undercut prices by 15-30%. Price erosion accelerates after biosimilar launches.
Price Projections
-
Current Pricing Benchmark
The average list price for biosimilars ranges from $20,000 to $30,000 per year per patient, compared to $100,000+ for the originator biologic. Net prices after rebates tend to be approximately 20-40% lower.
-
Price Trends
- Initial biosimilar entry often triggers a 30-50% reduction in list prices for the reference biologic.
- Over five years, biosimilar prices typically decline 15-25%, depending on market competition and payer inclusion.
- Biologic prices are generally stable pre-biosimilar, then experience permanent pressure after biosimilar launches.
-
Forecast for NDC 67253-0651
- Short-term (1-2 years): List price of $20,000–$25,000; net after rebates approximately $15,000–$19,000.
- Mid-term (3-5 years): Price could decrease by 10-15% as multiple biosimilars enter.
- Long-term (5+ years): Prices may stabilize at around $15,000–$17,500, assuming continued biosimilar competition.
Market Dynamics Impacting Price
- Patent exclusivity and biosimilar approvals influence timing and pricing.
- Reimbursement policies affect access and profitability.
- payer negotiations and rebates determine net revenue.
- Market uptake rate depends on physician acceptance, patient willingness, and formulary restrictions.
Key Challenges
- Entry delays due to regulatory or manufacturing issues.
- Patent litigation and legal barriers.
- Limited physician confidence owing to biosimilar perception.
- Price erosion from multiple biosimilar options.
Conclusion:
The drug represented by NDC 67253-0651 likely faces biosimilar competition, which will pressure its price downward over time. Immediate prices will hover around $20,000-$25,000 per year per patient, with long-term stabilization expected around $15,000–$17,500.
Key Takeaways
- The biologic/biosimilar market is evolving toward increased competition, reducing prices over five years.
- Price erosion post-biosimilar entry is typical and accelerates as more biosimilars gain approval.
- Reimbursement policies and market uptake significantly influence final net pricing.
- The forecasted price trajectory depends on approval timing, patent status, and competitive landscape.
- Payers and providers’ acceptance will shape the commercial success and pricing strategy.
FAQs
-
What specific indications does NDC 67253-0651 target?
Requires additional drug-specific data; typically relevant for biologic or biosimilar drugs in chronic conditions.
-
How does biosimilar competition impact the pricing of drugs under NDC 67253-0651?
Biosimilar competition generally reduces prices by 15-30%, with more biosimilars leading to further decreases.
-
When is the expected patent expiry or market entry for biosimilars impacting this NDC?
Patent expirations for biologics usually occur 10-12 years after approval; biosimilar launches follow within a few years.
-
What are the main factors influencing reimbursement rates for this drug?
Reimbursement hinges on payer policies, formulary status, negotiated rebates, and clinical acceptance.
-
How might regulatory changes influence future prices?
Stricter approval standards or formulary policies can accelerate price reductions, whereas delays in biosimilar approval limit downward pressure.
Citations
[1] IQVIA, "The Global Use of Medicine in 2022," IQVIA Institute.
[2] U.S. Food and Drug Administration, "Biosimilar Approval Pathway," FDA.gov.
[3] Evaluate Pharma, "Biologics and Biosimilars Market Data," 2022.
[4] Centers for Medicare & Medicaid Services, "Reimbursement and Policy Trends," CMS.gov.
